GlycoMimetics to Acquire Crescent Biopharma (Merger to Operate as Crescent Biopharma, Inc.)

Akers Biosciences and MyMD Pharmaceuticals Announce Definitive Merger Agreement

November 12, 2020

Pharmaceuticals

Akers Biosciences (NASDAQ: AKER) and MyMD Pharmaceuticals have entered into a definitive merger agreement that will combine the two companies into a single Nasdaq-listed company to be renamed MyMD Pharmaceuticals, Inc. The transaction, expected to close in H1 2021, gives current MyMD shareholders approximately 80% of the combined company and is intended to provide MyMD access to public capital and Akers' resources to accelerate development and commercialization of MyMD's immunotherapy pipeline.

HAS Healthcare Advanced Synthesis Acquires Cerbios-Pharma (Backed by 65 Equity Partners)

March 31, 2025

Healthcare Services

HAS Healthcare Advanced Synthesis SA (HAS) announced the planned acquisition of Cerbios-Pharma SA (Cerbios) to create a leading international CDMO group focused on contract development and manufacturing of APIs, HPAPIs and oncology-related therapies including ADCs. The deal is supported by 65 Equity Partners, which will become an approximately 40% shareholder alongside the Braglia family, pending regulatory and tax approvals.

SAB Biotherapeutics to Go Public via Merger with Big Cypress Acquisition Corp.

October 20, 2021

Biotechnology

SAB Biotherapeutics entered into a definitive business combination/merger agreement with Big Cypress Acquisition Corp. (a SPAC), with the combined company to operate as SAB Biotherapeutics and be listed on Nasdaq. Big Cypress stockholders approved the deal, and the transaction was expected to close on or about October 22, 2021, subject to customary conditions.

Candid Therapeutics to Merge With Rallybio (Creating Nasdaq-listed Candid Therapeutics)

March 5, 2026

Biotechnology

Clinical-stage biotechnology company Candid Therapeutics signed a merger agreement with Rallybio Corporation to create a combined company focused on developing T cell engager therapies for autoimmune diseases. The transaction is expected to close in mid-2026, pending customary approvals and conditions, and Candid also secured an oversubscribed private financing of more than $505 million led by healthcare institutional investors.

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.

Synsus Private Label Partners (Crescentia Capital) Acquires AmegA Sciences and React Industries

June 5, 2024

Agriculture

Crescentia Capital’s portfolio company Synsus Private Label Partners has acquired AmegA Sciences, LLC and React Industries, LLC, combining the businesses into Synsus’s manufacturing platform. The acquisition expands Synsus’s specialty liquid fertilizer, adjuvant and private-label chemical manufacturing footprint and product offerings for agriculture, turf & ornamental, and direct-to-consumer markets.